110 related articles for article (PubMed ID: 31329907)
1. The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma.
Baek MH; Park JY; Park Y; Kim KR; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Jpn J Clin Oncol; 2019 Aug; 49(8):719-726. PubMed ID: 31329907
[TBL] [Abstract][Full Text] [Related]
2. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
Leiser AL; Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi DS; Soslow RA
Gynecol Oncol; 2006 Apr; 101(1):86-91. PubMed ID: 16289259
[TBL] [Abstract][Full Text] [Related]
4. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma.
Yang Q; Falahati A; Khosh A; Mohammed H; Kang W; Corachán A; Bariani MV; Boyer TG; Al-Hendy A
Cells; 2022 Nov; 11(23):. PubMed ID: 36497061
[TBL] [Abstract][Full Text] [Related]
5. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.
Lusby K; Savannah KB; Demicco EG; Zhang Y; Ghadimi MP; Young ED; Colombo C; Lam R; Dogan TE; Hornick JL; Lazar AJ; Hunt KK; Anderson ML; Creighton CJ; Lev D; Pollock RE
Ann Surg Oncol; 2013 Jul; 20(7):2364-72. PubMed ID: 23334251
[TBL] [Abstract][Full Text] [Related]
6. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
7. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Akhan SE; Yavuz E; Tecer A; Iyibozkurt CA; Topuz S; Tuzlali S; Bengisu E; Berkman S
Gynecol Oncol; 2005 Oct; 99(1):36-42. PubMed ID: 15992918
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma.
Baek MH; Park JY; Park Y; Kim KR; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e30. PubMed ID: 29533018
[TBL] [Abstract][Full Text] [Related]
9. Neuropilin 1 in uterine leiomyosarcoma. Clinical and pathological analysis.
Bobiński M; Okła K; Kotarski J; Szumiło J; Polak G; Sobstyl M; Bednarek W
Ginekol Pol; 2018; 89(1):7-12. PubMed ID: 29411340
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
12. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas.
Lee CH; Roh JW; Choi JS; Kang S; Park IA; Chung HH; Jeon YT; Kim JW; Park NH; Kang SB; Song YS
Int J Gynecol Cancer; 2011 May; 21(4):668-72. PubMed ID: 21412163
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.
Zhai YL; Nikaido T; Toki T; Shiozawa A; Orii A; Fujii S
Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor II messenger RNA-binding protein-3 is an independent prognostic factor in uterine leiomyosarcoma.
Yasutake N; Ohishi Y; Taguchi K; Hiraki Y; Oya M; Oshiro Y; Mine M; Iwasaki T; Yamamoto H; Kohashi K; Sonoda K; Kato K; Oda Y
Histopathology; 2018 Apr; 72(5):739-748. PubMed ID: 29077232
[TBL] [Abstract][Full Text] [Related]
17. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma.
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Obermair A; Kimberger O; Czerwenka K
Gynecol Oncol; 2004 Jan; 92(1):175-9. PubMed ID: 14751154
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.
Chaiyawat P; Pruksakorn D; Phanphaisarn A; Teeyakasem P; Klangjorhor J; Settakorn J
Mod Pathol; 2018 Feb; 31(2):264-274. PubMed ID: 28984297
[TBL] [Abstract][Full Text] [Related]
20. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
